Opinion|Videos|October 15, 2024
Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For most patients with untreated, advanced, or metastatic EGFRmut+ NSCLC do you consider the combination of osimertinib and chemotherapy to be manageable from a safety and tolerability perspective?
- In your experience, how soon do patients become resistant to a third-generation, EGFR TKI?
- Based on the FLAURA2 study design, do you consider concurrent combination therapy superior to sequential treatment for the population of patients with untreated, advanced, metastatic, or recurrent NSCLC not amenable to resection or radiotherapy?
- Please explore the implications of additional mutations in patients with EGFRmut+NSCLC and the occurrence of EGFR mutations on ctDNA after treatment with osimertinib.
- How are you using ctDNA in decision making and practice among these patients with EGFR mutated NSCLC for osimertinib and chemo + ostimertinib?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5